China
· Delayed Price · Currency is CNY Hualan Biological Vaccine Statistics
Total Valuation
Hualan Biological Vaccine has a market cap or net worth of CNY 11.71 billion. The enterprise value is 9.47 billion.
| Market Cap | 11.71B |
| Enterprise Value | 9.47B |
Important Dates
The last earnings date was Tuesday, October 29, 2024.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | Jun 14, 2024 |
Share Statistics
Hualan Biological Vaccine has 595.00 million shares outstanding. The number of shares has increased by 0.21% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 595.00M |
| Shares Change (YoY) | +0.21% |
| Shares Change (QoQ) | -0.67% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 3.14% |
| Float | 76.64M |
Valuation Ratios
The trailing PE ratio is 23.80 and the forward PE ratio is 12.72.
| PE Ratio | 23.80 |
| Forward PE | 12.72 |
| PS Ratio | 7.16 |
| PB Ratio | 1.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.85 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.06, with an EV/FCF ratio of 13.63.
| EV / Earnings | 19.03 |
| EV / Sales | 5.74 |
| EV / EBITDA | 16.06 |
| EV / EBIT | 21.29 |
| EV / FCF | 13.63 |
Financial Position
The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.08 |
| Quick Ratio | 2.83 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | 0.43 |
| Interest Coverage | 72.94 |
Financial Efficiency
Return on equity (ROE) is 8.21% and return on invested capital (ROIC) is 4.37%.
| Return on Equity (ROE) | 8.21% |
| Return on Assets (ROA) | 3.60% |
| Return on Capital (ROIC) | 4.37% |
| Revenue Per Employee | 2.14M |
| Profits Per Employee | 646,251 |
| Employee Count | 770 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.36 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.28% in the last 52 weeks. The beta is 0.80, so Hualan Biological Vaccine's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -30.28% |
| 50-Day Moving Average | 18.68 |
| 200-Day Moving Average | 20.21 |
| Relative Strength Index (RSI) | 50.26 |
| Average Volume (20 Days) | 5,242,408 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hualan Biological Vaccine had revenue of CNY 1.65 billion and earned 497.61 million in profits. Earnings per share was 0.83.
| Revenue | 1.65B |
| Gross Profit | 1.29B |
| Operating Income | 444.92M |
| Pretax Income | 577.85M |
| Net Income | 497.61M |
| EBITDA | 589.68M |
| EBIT | 444.92M |
| Earnings Per Share (EPS) | 0.83 |
Balance Sheet
The company has 2.54 billion in cash and 300.00 million in debt, giving a net cash position of 2.24 billion or 3.76 per share.
| Cash & Cash Equivalents | 2.54B |
| Total Debt | 300.00M |
| Net Cash | 2.24B |
| Net Cash Per Share | 3.76 |
| Equity (Book Value) | 6.09B |
| Book Value Per Share | 10.24 |
| Working Capital | 3.13B |
Cash Flow
In the last 12 months, operating cash flow was 750.00 million and capital expenditures -54.93 million, giving a free cash flow of 695.08 million.
| Operating Cash Flow | 750.00M |
| Capital Expenditures | -54.93M |
| Free Cash Flow | 695.08M |
| FCF Per Share | 1.17 |
Margins
Gross margin is 77.91%, with operating and profit margins of 26.97% and 30.17%.
| Gross Margin | 77.91% |
| Operating Margin | 26.97% |
| Pretax Margin | 35.03% |
| Profit Margin | 30.17% |
| EBITDA Margin | 35.75% |
| EBIT Margin | 26.97% |
| FCF Margin | 42.14% |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 2.98%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 2.98% |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 67.84% |
| Buyback Yield | -0.21% |
| Shareholder Yield | 2.77% |
| Earnings Yield | 4.20% |
| FCF Yield | 5.94% |
Stock Splits
The last stock split was on June 7, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 7, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
Hualan Biological Vaccine has an Altman Z-Score of 6.71.
| Altman Z-Score | 6.71 |
| Piotroski F-Score | n/a |